TC
BMRN icon

Trust Company’s BioMarin Pharmaceuticals BMRN Stock Holding History

Trust Company’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57 Hold
1
– – ﹤0.01% 899
2026
Q1 		$56 Hold
1
– – ﹤0.01% 894
2025
Q4 		$59 Buy
+1
New +$54 ﹤0.01% 878

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Trust Company's BMRN Position: Q2 2026 in Review

Trust Company held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 1 share worth $57. The position accounts for ﹤0.01% of the portfolio, ranked #899.

Trust Company first reported a position in BMRN in Q4 2025 and has held it in 3 quarters since. The position peaked at $59 in Q4 2025. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Trust Company held 1 share of BioMarin Pharmaceuticals worth $57 as of Q2 2026.
  • Trust Company left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Trust Company's portfolio in Q2 2026, its #899 holding.
  • Trust Company first reported a position in BioMarin Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Trust Company's BioMarin Pharmaceuticals position peaked at $59 in Q4 2025.
  • 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Trust Company's 13F filing for Q2 2026, filed 10 Jul 2026.